European Journal of Medicinal Chemistry · 2019 · 20 citations · 21 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationEnzyme InhibitionLigand BindingLigand-based DesignMolecular DockingProtein-ligand DockingTyrosine Kinase InhibitorsAlk InhibitionAlk Point MutationsAnaplastic Lymphoma Kinase InhibitionDual-target InhibitorsKinase Inhibitor Library DesignProperty-based Drug DesignRos1 InhibitorsRos1-targeted Therapy
21
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations
Medicine, Oncology, Pharmacology +14
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +12
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama, Alice T. Shaw, Tahsin Khan et al. · Science Translational Medicine · 2012 · 1.3K citations
Medicine, Oncology, Pharmacology +17